Literature DB >> 6430995

The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin.

S H Lee, B B Aggarwal, E Rinderknecht, F Assisi, H Chiu.   

Abstract

Highly purified preparations of rHuIFN-gamma and HLT synergistically inhibit the in vitro proliferation of WI38VA13 cells, a SV40 virus-transformed derivative of the human cell line W138. The growth of nontumorigenic WI38 cells, established from normal diploid embryonic lung tissue, was not inhibited under identical incubation conditions; rMuIFN-gamma and HLT have the same in vitro effects on the murine melanoma B16. Thus, the combination of rMuIFN-gamma and HLT synergistically inhibits the growth of B16 cells, although incubation with either lymphokine alone has no significant anti-proliferative effect. Flow cytometric analysis of the cell cycle of asynchronous cells indicates that when B16 melanoma cells are treated with rMuIFN-gamma and HLT in combination, more cells accumulate in the G0/G1 phase than when the cells are treated with rMuIFN-gamma alone. It appears that populations of rapidly proliferating tumor cells, which normally contain a large percentage in the S+G2+M phases of the cell cycle, become arrested in the quiescent G0/G1 phase by the combination of IFN-gamma and HLT, resulting in the inhibition of cell growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430995

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Enhancement of thyrocyte HLA class II expression by thyroid stimulating hormone.

Authors:  I Todd; R Pujol-Borrell; L J Hammond; J M McNally; M Feldmann; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

Review 2.  Immunological aspects of antiviral therapy.

Authors:  M Peters
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Lymphotoxin production by regional lymph node lymphocytes in patients with uterine cervical cancer.

Authors:  K Matsunaga; H Mashiba; A Kurano; S Jimi
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

Review 4.  Resistance of tumor cells to tumor necrosis factor.

Authors:  H M Shepard; G D Lewis
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

5.  Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection.

Authors:  D M Williams; L F Bonewald; G D Roodman; G I Byrne; D M Magee; J Schachter
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon gamma followed by an analogue (GLA-60) to synthetic lipid A subunit.

Authors:  I Saiki; H Maeda; J Murata; N Yamamoto; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells.

Authors:  K Iwasaki; S A Toms; G H Barnett; M L Estes; M K Gupta; B P Barna
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

8.  Effects of gamma interferon, tumor necrosis factor alpha, and interleukin-2 on infection and proliferation of Theileria parva-infected bovine lymphoblasts and production of interferon by parasitized cells.

Authors:  J C DeMartini; C L Baldwin
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.

Authors:  J S Shin; J H Park; J D Kim; J M Lee; S J Kim
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

Review 10.  Regulatory functions for murine intraepithelial lymphocytes in mucosal responses.

Authors:  H Kiyono; K Fujihashi; T Taguchi; W K Aicher; J R McGhee
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.